The Calpain Hypothesis of Neurodegeneration: Evidence for a Common Cytotoxic Pathway
- 1 September 1997
- journal article
- research article
- Published by SAGE Publications in The Neuroscientist
- Vol. 3 (5), 314-327
- https://doi.org/10.1177/107385849700300513
Abstract
Calpain's general function and pathogenic role in the CNS are reviewed. Collectively, the literature indicates that calpain proteolysis plays a common and important role in a variety of acute neurodegenerative conditions, including focal ischemia (stroke), global ischemia, traumatic brain injury, and spinal cord injury. This evidence indicates that 1) calpain is activated in an abnormally sustained fashion during cellular events commonly associated with neurodegeneration (e.g., excessive interstitial glutamate and cytosolic calcium); 2) many of calpain's preferred substrates are degraded as important components in these neurodegenerative conditions; 3) calpain activation occurs early in the pathogenic cascade of each, prior to onset of substantial cell death; and 4) calpain inhibitors can effectively reduce the severity of neuronal damage and loss of function normally associated with these acute neurodegenerative perturbations. Calpain proteolysis is also implicated in chronic neurodegenerative diseases, with the strength of current evidence varying among specific diseases. The evidence accumulated for a plausible role in Alzheimer's disease (AD) is currently the strongest. For example, empirical links have been established between abnormal calpain proteolysis and 1) the cellular formation of classic Alzheimer's pathology, such as β-amyloid plaques, neurofibrillary tangles, and Alz-50 immunoreactivity; 2) the brain regions with greatest concentrations of AD-related pathology; and 3) the degeneration of key brain pathways vulnerable in the early stages of the disease. Similar, though less extensive, evidence exists for a potential role of abnormal calpain proteolysis in Parkinson's disease. Finally, for several other chronic neurodegenerative conditions (e.g., Huntington's disease and amyotrophic lateral sclerosis), early evidence is emerging that calpain may also play some pathogenic role. Thus, these data support the possibility that uncontrolled calpain proteolysis may contribute to and/or accelerate the loss of neurons associated with a wide range of neurodegenerative conditions and may, therefore, represent an important, final common cytotoxic pathway for many diverse forms of neurodegeneration. NEUROSCIENTIST 3:314–327, 1997Keywords
This publication has 76 references indexed in Scilit:
- Time-Related Neuronal Changes following Middle Cerebral Artery Occlusion: Implications for Therapeutic Intervention and the Role of CalpainJournal of Cerebral Blood Flow & Metabolism, 1995
- Calpain inhibitors reduce depolarization induced loss of tau protein in primary septo-hippocampal culturesNeuroscience Letters, 1995
- Local Cerebral Glucose Utilization and Cytoskeletal Proteolysis as Indices of Evolving Focal Ischemic Injury in Core and PenumbraJournal of Cerebral Blood Flow & Metabolism, 1995
- Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration.Stroke, 1994
- New era of calpain researchFEBS Letters, 1994
- Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia.Stroke, 1994
- Microtubule-Associated Protein 2 Levels Decrease in Hippocampus Following Traumatic Brain InjuryJournal of Neurotrauma, 1992
- Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissueNeurobiology of Aging, 1990
- Alzheimer's Disease: A Disorder of Cortical Cholinergic InnervationScience, 1983
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982